Corsano Health to launch CardioWatch 287-2 at MEDICA

Corsano Health is launching the company’s second-generation wearable device that accurately...

Image credit: Corsano Health

Corsano Health is launching the company’s second-generation wearable device that accurately measures eight vital parameters and makes raw PPG and ACC data available for further analysis by third-party medical algorithm developers.

THE HAGUE, THE NETHERLANDS, October 20, 2022 -- Today, Corsano Health, a leading MedTech company developing, producing, and marketing medical grade continuous health monitoring announced the launch of its CardioWatch 287 at MEDICA 2022, Booth 12D33.

MEDICA is the world‘s largest medical marketplace annually organized in Düsseldorf, taking place this year from 14 – 17 November.

Corsano’s CardioWatch 287 accuracy of a state-of-the-art bracelet has been validated in eight third-party clinical investigations. “The independent validations of Corsano Health’s CardioWatch 287 is important evidence to prove accurate measurement of five vital parameters. Moreover, Corsano offers access to raw PPG and ACC data for further analysis to academic researchers and contract research organizations. Corsano’s non-invasive ergonomic wearables deliver medically validate data with superior patient compliance.” said Drs. Peter Stas, CEO of Corsano Health. "Additionally, patient satisfaction surveys conducted at the closure of the studies cite convenience and ease to use of the CardioWatch 287 devices.”

Due to their non-intrusive and convenient nature, wearable devices like Corsano’s CardioWatch 287 have great potential for high volume accessible long-term monitoring of at-risk patients.

About Corsano Health

Corsano Health, based in The Netherlands with offices in Switzerland, is a leading wearable MedTech company developing, producing and marketing medical smart monitoring devices designed to measure vital parameters 24/7 using wireless, non-invasive, and medical-grade technology. The Corsano brand name is derived from in corpore sano (in a healthy body). Corsano’s CardioWatch 287 is a cardiac arrhythmia screening system that provides a simple and effective method for continuous monitoring of vital parameter measurements (i.e., Heart Rate, RR Intervals, Respiration Rate, SpO2, Sleep, Activity, ECG, BIOZ, Core Body Temperature, Cuffless Blood Pressure). More information at http://www.corsano.com

Jürgen Thalmayer
October 24, 2022

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

Picosun Successfully Uses its ALD Technology to Manufacture Lithium Ion Thin Film Battery

Picosun Group, a Finnish company, well-known for its AGILE ALD (Atomic Layer Deposition)...

Fertility Tracking App Flo Raises $50M Series B Round, Bringing Company Valuation to $800M

Fertility tracking app Flo announced it closed $50M in a Series B financing, bringing the total ...

RealWear Navigator Z1 for Frontline Operations

The Navigator Z1 a new product that streamlines the company's array of frequently used XR products.

FC Barcelona and Allianz SE Partner with Hexoskin for Sleep Study

FC Barcelona and global insurance company Allianz SE will jointly develop innovative projects.
Discover more